DRUG DISCOVERY SUMMIT: Enabling Early Stage Drug Discovery and Venture Creation

Event Program
Tuesday June 11, 2019
1:00 – 6:00 PM

JLABS@Toronto
MaRS Centre, West Tower
661 University Avenue, Suite 1300
Toronto, ON, Canada M5G 0B7

POWERED BY:
MaRS Innovation and our partner Evotec SE are pleased to welcome you to our inaugural LAB150 Drug Discovery Summit. We would like to thank Allan Miranda and the JLABS team for hosting us here today in this spectacular facility!

It has been 18 months since we launched LAB150, a program designed to enable translation of academic discoveries into medicines from MaRS Innovation (MI) Members. With five projects approved and funded and one project graduated from the program and negotiating follow-on investment, we are off to an incredible start! The LAB150 program, paired with MI’s venture creation and investment model, provides a leading platform for life sciences venture creation and growth in Canada. Over the last decade, MI has created over 50 companies that have attracted and retained seasoned management, created over 400 STEM jobs and raised over $350M in direct third-party capital. With LAB150, we look forward to building on this success in the coming decade and beyond.

Today you will hear from entrepreneurs and scientists regarding their experiences with the LAB150 program. In addition, we are pleased to be joined by scientific experts from Evotec who will share emerging trends in the drug discovery space. Last but not least, early stage investors will share their tips and tricks for securing capital for building therapeutic ventures in Canada.

We trust this event will be informative for you as an academic scientist in our ecosystem and will support our common interests in drug discovery and translation. Please connect with the LAB150 team to share your ideas so, together, we can identify and develop Canada’s next life sciences venture. It will be an exciting and informative afternoon, thank you for joining us!

Sincerely,

Rafi Hofstein, PhD
President and CEO
MaRS Innovation
# AGENDA

## 1:00PM – 1:30PM
Registration

## 1:30PM – 1:40 PM
**Opening Remarks + Thanks to JLABS**
Allan Miranda, Head of JLABS@Canada  
Rafi Hofstein, President and CEO, MaRS Innovation  
Stephanie Oestreich, Executive Vice President, North American BRIDGEs Partnerships, Evotec SE

## 1:40PM – 2:10PM
**LAB150 Information Session**
*Speakers: Parimal Nathwani, Vice President, MaRS Innovation  
Stephanie Oestreich, Executive Vice President, North American BRIDGEs Partnerships, Evotec SE*

## 2:10PM - 2:40PM
**Two Case Studies of Collaboration between MaRS Innovation and Evotec:**
- **Company Creation – Fibrocor Therapeutics**  
  *Speaker: Mark Steedman, CEO*
- **First LAB150 Project – KaliDerm: The LAB150 Route to Success**  
  *Speaker: Ioannis Prassas, Scientist*

## 2:40PM – 2:50PM
Networking Break

## 2:50PM – 3:40PM
**Emerging Trends from Evotec Experts:**
1. The Changing Landscape of Drug Discovery: Managing Risk and New Modalities  
   *Iva Toudjarska, Senior Vice President, North American BRIDGEs Partnerships, Evotec SE*
2. Emerging Trends in Oncology Drug Discovery and Development  
   *Ashley Jarvis, Vice President, Medicinal Chemistry, Evotec SE  
   Fraser McIntosh, Head, In vivo Biology, Evotec SE*

## 3:40PM – 4:30PM
**Early Stage Drug Discovery Investor Panel**
*Moderator: Parimal Nathwani, Vice President, MaRS Innovation*  
*Panelists: Cynthia Lavoie, Co-founder and Managing Director, AllosteRx Capital  
Ines Holzbaur, Co-founder and Managing Partner, AmorChem  
Michael Crackower, Entrepreneur-in-residence, Versant Ventures  
Bill Newsome, Vice President, Strategic Business Development, Evotec SE*

## 4:30PM – 4:40PM
**Closing Remarks**
Parimal Nathwani, Vice President, MaRS Innovation

## 4:40PM – 6:00PM
Networking Reception
AmacaThera, a UTEST portfolio company, raised $3.25M to develop a novel delivery technology that could eliminate the need to deliver addictive pain medications following surgery – a critical source of the opioid crisis.

Fibrocor Therapeutics entered into a licensing and collaboration deal with Belgian-Dutch company Galapagos NV for the development of therapeutics targeting fibrotic diseases of the kidney and other organs.

Forbius Therapeutics advanced its lead antibody drug conjugate targeting EGFR (AVID100) into Phase II clinical trials for oncology and its antibody targeting TGF-beta pathway (AVID200) into Phase I trials for fibrosis.

Phenomic AI, a UTEST portfolio company, raised $1.5M in financing to advance the development of its artificial intelligence-based drug discovery platform.

Triphase Accelerator announced a new strategic collaboration with Celgene for the development of a pre-clinical asset targeting WDR5 for the treatment of blood cancers. Celgene paid US$40M upfront and US$940M will be tranched in success-based milestone payments and royalties to Triphase.

Vasomune Therapeutics secured financing and a co-development deal with Japan-based AnGes Inc. to take lead product AV-001 through Phase II clinical proof of concept. The company also recruited Doug Hamilton, a seasoned biotechnology executive from the Bay area, as its Toronto-based President and CEO.

Zucara Therapeutics completed its pre-IND meeting with the FDA for development of its lead product ZT-01 to treat insulin induced hypoglycemia. The company is on track to initiate Phase I clinical trials by the end of 2019.

LAB150 has invested in five drug discovery projects – one project from each of University of Toronto, Hospital for Sick Children, University Health Network, Lunenfeld Tanenbaum Research Institute, and Centre for Addiction and Mental Health.

The first LAB150 project entitled “Developing novel Kallikrein-targeting agents for the treatment of skin inflammatory conditions” has been successfully completed on time and on budget and is currently negotiating for follow-on investment.
LAB150 TEAM

Parimal Nathwani  
Vice President, MaRS Innovation

Stephanie Oestreich  
Executive Vice President, North American BRIDGEs Partnerships, Evotec SE

Tim Key  
Manager, Technology & Venture Development, MaRS Innovation

Jasmine Dautovich  
Manager, Technology & Venture Development, MaRS Innovation

Phil Goldbach  
Manager, IP, Technology & Venture Development, MaRS Innovation
LAB150 accelerates academic research towards commercial outcomes by providing funding and access to pharmaceutically validated platforms and expertise

LAB150 is a drug development collaboration between MaRS Innovation and Evotec SE developed to accelerate Toronto’s academic research into market-ready products. With a combined multi-million-dollar financial commitment by MaRS Innovation and Evotec SE, this newly formed partnership accelerates the development and commercialization of your drug discovery research programs and technologies with award amounts up to 400k USD.

For more information, visit: www.lab150.com. If you are interested in participating in the LAB150 program, email: info@lab150.com or phone: 647-260-7897.

Drug discovery activities offered through LAB150 partnering:

- Target ID and validation
- Structural biology
- Medicinal chemistry and Lead ID
- Proteomics
- High throughput screening

- Compound management
- In vitro pharmacology
- In vivo pharmacology
- ADME-tox and DMPK
Mark Steedman, MBA
President and CEO, Fibrocor Therapeutics

Mark Steedman has over 15 years of operating experience in medical start-ups where he led the successful commercialization efforts of key therapies in renal dialysis and radiology. Mark has raised over $20M in early stage funding and has inked partnership deals with both pharma and medtech multi-national companies.

Before joining Fibrocor Therapeutics, Mark was a founder and VP, Business Development, at Interface Biologics, a spinout of the University of Toronto where he was responsible for intellectual property development, early stage fund raising and operational activities. Prior to Interface Biologics, Mark was an entrepreneur-in-residence at Genesys Capital, a VC firm in Toronto.

Mark received his MBA from Wilfrid Laurier University and his BA in Biology and BSc in Applied Science concurrently at Queen’s University in Kingston. Mark currently sits on the boards of OBIO and Fibrocor and previously mentored early stage companies at the Ontario Brain Institute.
Ioannis Prassas, PhD
Scientist, Mount Sinai Hospital
Scientific Leader of the KaliDerm project

Ioannis Prassas received his PhD from the Department of Laboratory Medicine and Pathobiology, University of Toronto, Canada (2012). For more than 15 years, his research focus has been on the elucidation of the therapeutic roles of human proteases in skin pathologies.

Working closely with professor Eleftherios Diamandis and his team, Ioannis has offered indispensable new insights into the regulation, expression and mechanistic roles of a group of 15 enzymes, originally cloned by their team and collectively known as the human tissue kallikreins (KLKs). Using a variety of cutting-edge molecular biology techniques, Ioannis has shown that KLKs are major players in the initiation and progression of skin inflammation and represent attractive enzymes for therapeutic targeting.

Currently a staff scientist at Mount Sinai Hospital, Ioannis is leading the scientific work of the KaliDerm project which was launched with the scope of developing the first generation of KLK-targeting compounds as novel topical skin inflammatory therapeutics.
Iva Toudjarska, PhD
Senior Vice President, North American BRIDGEs Partnerships, Evotec SE

Prior to joining Evotec, Iva spent 6 years in Biopharma strategy consulting enabling clients to develop strategic insights and decisions pertaining to new product development, portfolio prioritization, clinical development, commercial opportunity assessments, as well as due diligence for buy-side and sell-side opportunities. Previously, she was a founding employee at Alnylam Pharmaceuticals, the leader in RNAi therapeutics. During her 9 year tenure at Alnylam, as part of a multi-disciplinary team, Iva advanced several programs to clinic, most notably ALN-RSV (a virology program) and ALN-VSP (an oncology program). Iva led the initiation of two hematology programs, ALN-AT3 for the treatment of hemophilia (currently in clinic) and ALN-TMP for the treatment of beta-thalassemia.

Iva earned a Doctor of Philosophy from the Bulgarian Academy of Sciences in Molecular Genetics and a Masters of Business Administration from F.W. Olin Graduate School of Business at Babson College.
Ashley Jarvis, PhD, FRSC
VP, Medicinal Chemistry, Evotec SE

Ashley is a synthetic organic chemist by training and has further developed his career in industrial chemistry and drug discovery with over 20 years of experience. His speciality area is medicinal chemistry where he has led project teams that have contributed to the nomination of several (“small molecule”) pre-clinical drug candidates, across different disease areas. Ashley’s experience covers both academic and private sectors within the UK and New Zealand, including Domainex Ltd., The Wolfson Institute for Biomedical Research, Industrial Research Ltd. and Oxford Asymmetry International.

Ashley is a Medicinal Chemistry Department Head at Evotec (UK) Ltd., having held this position since joining the company in 2017. In addition to Ashley’s line management responsibilities, he provides scientific leadership and oversight for Evotec’s contribution to integrated drug discovery projects and nurtures collaborative relationships with both academic and industrial partners.

Ashley earned a PhD in Synthetic Organic Chemistry and a BSc Chemistry (first class) from the University of Bristol.

Fraser McIntosh, BSc
Head, In vivo Biology, Evotec SE

Fraser McIntosh has over 25 years of experience in the drug discovery sector, primarily in the pre-clinical setting but also including clinical projects up to Phase 2b. He was also part of the discovery team which lead to the identification of the PDE-5 inhibitor, Viagra.

Before joining Evotec, Fraser established a Discovery Services division at Charles River Canada and prior to that held various positions at Pfizer and AstraZeneca, leading operational and project-based teams which delivered more than 15 pre-clinical candidates spanning therapeutic areas across CNS/Pain, Respiratory & Inflammation, Fibrosis and Cardiometabolic. Since joining Evotec in 2015, Fraser has operational responsibility for global in vivo pharmacology at five EU sites, covering all major therapeutic areas of the company.

Fraser received his BSc Pharmacology at Aberdeen University and sits on the scientific board of Fibrocor Therapeutics.
Cynthia Lavoie, PhD
Co-founder and Managing Director, AllosteRx Capital

Dr. Lavoie is co-founder and Managing Director of AllosteRx Capital, where she focuses on early-stage investments in therapeutics and therapeutic technologies sourced from under-ventured regions and institutions in the US and Canada. She is also currently a member of the Investment Committee for AMORCHEM II L.P., a fund managed by the AmorChem Group in Montreal and serves as an independent on the board of Fibrocor Therapeutics in Toronto.

In advance of her role with AllosteRx, Dr. Lavoie was a General Partner with global investment firm TVM Life Science Management where she was responsible for deal making, deal execution and for the management of portfolio companies in the U.S. and Canada. Dr. Lavoie founded and led investments into Kaneq Bioscience, Mediti Pharma and FAAH Pharma. She served on the board of Kaneq and chaired the boards of FAAH and Mediti. Dr. Lavoie also merged assets and led investments into Acer Therapeutics, a late-stage orphan drug company located in Cambridge, MA, and served on the board of directors.

Prior to this, Dr. Lavoie was with VG Partners, a large Canadian private equity firm, where her most recent role was as Partner and head of life sciences. She served on the boards of therapeutics and device companies including Cytochroma (sold to Opko Health) and Trillium Therapeutics (NASDAQ: TRIL). Dr. Lavoie also had a direct role in the sale of VisualSonics, an imaging company, to SonoSite Inc. (now Fujifilm SonoSite). Previously, Dr. Lavoie was a marketing strategy consultant with drug/device developer Vasogen (merged with Intellipharmaceutics; NASDAQ: IPCI).

Dr. Lavoie completed her PhD at McGill University and carried out academic and commercially focused research at the University of Texas Southwestern Medical Center. Dr. Lavoie graduated with a first-class honors MBA from the Rotman School of Management.
Inès is Co-founder and Managing Partner of AmorChem, an early stage venture fund. As co-founder, Ines contributed significantly to the conception of the fund’s innovative early-stage life sciences investment model, as well as to the development of its operations and daily activities. Her input on processes have had an important impact on the success of the fund. Ines was responsible for several investments and was actively involved in a major collaboration between Dr. Pascal Chartrand and Hoffman LaRoche. She also participated in the sale of an asset to Vertex Pharmaceuticals. In addition to pharma transactions, Ines led the spinning out of SpecificiT Pharma. Inès currently sits on the board of NuChem Therapeutics, a medicinal chemistry service provider. Her role in the life sciences ecosystem extends beyond AmorChem; she is a member of the College of Reviewers of the Canadian Institutes for Health Research as well as a board member of the Centre Québécois d’Innovation en Biotechnologie and of Réseau-Capital. She is also a participant on Montreal InVivo committees.

Having joined the venture capital industry in the late ‘90s as an intern in the GeneChem family of funds, Ines rapidly rose to General Partner.

Inès holds a PhD in chemistry from the University of Cambridge.
Michael Crackower, PhD
Entrepreneur-in-Residence, Versant Ventures

Prior to joining Versant, Michael worked at Celgene in Cambridge MA, where he held the position of executive director and head of late drug discovery and fibrosis research. In that role, he shaped the strategy for Celgene’s autoimmunity, inflammation and fibrosis programs. He also served as a mentor to the company’s program leads and oversaw preclinical drug discovery in the immunology and Inflammation therapeutic area. Prior to Celgene, Michael was director of research for tissue injury and fibrosis at Biogen. Here Michael joined the company to help build a new department and successfully built a high functioning drug discovery department with a robust drug discovery pipeline. Michael spent much of his early career working at Merck (Montreal and Boston) as a director in the respiratory and immunology department. In addition to leading several drug discovery programs resulting in 5 molecules entering clinical development, Michael had an instrumental role in guiding disease area strategies for the Franchise.

As an entrepreneur-in-residence based in Toronto, Canada, Michael’s primary role is to identify opportunities for new biotech start-ups and build a Toronto based company. Michael’s experience in exploring in-licensing opportunities and conducting due diligence as well as being a member of numerous joint steering committees directing company/start-up relationships are essential to this role.

Michael has a BSc in biochemistry from the University of Western Ontario and a PhD in molecular and medical genetics from the University of Toronto, working in the lab of Dr. Lap-Chee Tsui and the hospital for Sick Children. Michael conducted his postdoctoral studies at the Amgen Institute (PMH), where he made seminal discoveries in cardiovascular and reproductive biology.
Bill has been in the academic and industrial drug discovery arena for nearly thirty years. Bill has extensive knowledge of the global drug discovery and biopharmaceutical landscape, drug discovery process and industry and technology trends. This has led to a consistent record of successful program implementation, from $100M+ shared-risk, integrated drug discovery collaborations to multi-million dollar custom technology development programs, new co formation, academic commercialization programs and requisite organizational goal accomplishment.

After performing research at University of Freiburg, Bill started his career at Harvard’s Joslin Diabetes Center before moving to Pfizer to pursue drug development in diabetes and metabolic disease. He transitioned to West Coast technology companies holding numerous positions in business development at Stratagene, DiscoveRx and start-up Blueshift Biotechnologies, all of which underwent successful acquisitions.

Bill earned his BS from Colorado State University and MA from Brown University. He currently sits on the board of Fibrocor Therapeutics.
THANK YOU TO OUR PARTNERS!